Hiro‐omi Kanayama

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification

Masayuki Takahashi, Daniel R. Rhodes, Kyle A. Furge et al. · Proceedings of the National Academy of Sciences · 2001 · 403 citations · Full text

Ccrcc Tumors, Pathology, Gene Expression Profiling +16

Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer

Hiro‐omi Kanayama, Kinya Yokota, Yasushi Kurokawa et al. · Cancer · 1998 · 190 citations

Molecular subclassification of kidney tumors and the discovery of new diagnostic markers

Masayuki Takahashi, Ximing J. Yang, Jun Sugimura et al. · Oncogene · 2003 · 182 citations · Full text

Tumor Biology, Kidney Tumors, Urology +10

Role of the vitamin D receptor in FGF23 action on phosphate metabolism

Yoshio Inoue, Hiroko Segawa, Ichiro Kaneko et al. · Biochemical Journal · 2005 · 166 citations · Full text